QUYNH NGUYEN: Open Payments
NPI 1336676949 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,809 in 73 payments from 31 companies in 2025. Trend: 2023 $597 · 2024 $1,150 · 2025 $1,809
Food & beverage: $1,809
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $319 |
| Celgene Corporation | 7 | $173 |
| GENZYME CORPORATION | 5 | $124 |
| Daiichi Sankyo Inc. | 3 | $102 |
| Merck Sharp & Dohme LLC | 4 | $99 |
| AstraZeneca Pharmaceuticals LP | 5 | $95 |
| Incyte Corporation | 4 | $83 |
| Stemline Therapeutics Inc. | 4 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $77 |
| SOBI, INC | 3 | $72 |
Products named: RYBREVANT, REBLOZYL, AYVAKIT, Enhertu, Orserdu, Nubeqa, KEYTRUDA, Doptelet.
Industry payments across TX — which companies pay providers there.
